The United Laboratories International Holdings' (HKG:3933) Liraglutide injection was approved by China's National Medical Products Administration for blood glucose control in adults with type 2 diabetes.
The drug, developed by subsidiary Zhuhai United Bio-Pharmaceutical, can be used alone or with metformin or sulfonylurea for patients needing additional control, according to a Friday filing with the Hong Kong bourse.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.